Comparative Pharmacology
Head-to-head clinical analysis: CURRETAB versus DELALUTIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CURRETAB versus DELALUTIN.
CURRETAB vs DELALUTIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Progesterone receptor agonist; induces secretory changes in endometrium, inhibits pituitary gonadotropin secretion, and has anti-estrogenic effects.
Progestogen; suppresses gonadotropin secretion, induces secretory endometrium, inhibits uterine contractions.
5 mg orally once daily for 10 consecutive days per cycle, beginning on day 16 of the menstrual cycle.
Hydroxyprogesterone caproate: 250-500 mg IM weekly, starting at 16-20 weeks gestation and continuing until 37 weeks or delivery, for prevention of preterm birth in women with singleton pregnancy and prior spontaneous preterm birth.
None Documented
None Documented
Terminal elimination half-life of medroxyprogesterone acetate (MPA) is approximately 12-17 hours (mean ~14 h) for oral administration; with intramuscular depot, half-life extends to ~6-7 weeks due to slow absorption from injection site
Terminal elimination half-life approximately 5.5 days (range 3-7 days), supporting weekly intramuscular dosing for sustained progestational effect.
Primarily renal (60-70% as metabolites, <10% unchanged); biliary/fecal (20-30%)
Primarily renal; conjugated metabolites excreted in urine (50-60%) and bile/feces (30-40%).
Category C
Category C
Progestin
Progestin